Turmeric for Memory Impairment and Cognition (TURMEMIC)

A Double Blind, Parallel, Placebo-controlled, Randomised Clinical Trial to Evaluate the Efficacy of Turmipure Gold® to Improve Cognitive Performance in Healthy Aging.

The objective of the study is to test the capacity of acute and chronic supplementations of Turmipure GOLD® to improve cognitive performance in healthy aging

Study Overview

• Status: Completed
• Conditions: Stress; Cognitive Change; Mood
• Intervention / Treatment: Dietary supplement: Turmipure Gold®; Dietary supplement: Placebo

Detailed Description

The aim of this clinical study is to determine whether oral administration of Turmipure GOLD® can contribute to the short- and long-term improvement of cognitive functions, including memory and attention, in subjects with age-associated memory impairment.

• Study Type: Interventional
• Enrollment (Actual): 568
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Ireland
  • Cork, Ireland, T23 R50R
    • Atlantia Food Clinical Trials

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 60 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Consent to the study and willing/able to comply with study product
• Males and females aged ≥ 60 and ≤ 85 years old

• Participants with subjective memory impairment, with preserved global cognitive functions, everyday activities, and no dementia, fulfilling age-associated memory impairment criteria based on the following National Institute of Mental Health criteria (AAMI, Crook 1986):

  1. Subjective memory complaint reflected in everyday difficulties (gradual) confirmed with a MAC-Q ≥25
  2. Memory loss confirmed by a 1st degree relative or life-partner
  3. Memory test performance that is at least 1SD below the mean established for healthy adults on a standardised test of secondary memory (VPA I and II portions of the Wechsler Memory Scale IV)
  4. Evidence of adequate intellectual function as determined by the Vocabulary subset of the Wechsler Adult Intelligence Scale
  5. Absence of dementia, as determined by the Telephone - Mini-Mental State Examination (MMSE) predicted in person score ≥24
• Not suffering from depression or anxiety, as determined by the Hospital Anxiety and Depression Scale (HADs) score of ≤7 for both depression and anxiety
• With a BMI between 18 and 32 kg/m²
• With a glycated haemoglobin/A1C score ≤ 5.7 %
• Willing to maintain existing dietary, body weight, and physical activity patterns throughout the study period

Exclusion Criteria:

• Abnormal laboratory test results of clinical significance
• With significant cardiovascular history, or significant cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, or metabolic/endocrine disorders or other disease that would preclude supplement ingestion and/or assessment of safety and the study objectives, as deemed exclusionary by the Principal Investigator
• With history of major head trauma, chronic traumatic encephalopathy, epilepsy, cerebrovascular disease, stroke or clinically diagnosed with mild cognitive impairment or dementia (such as Alzheimer's Disease according to the NINCDS-ADRDA guidelines), acute psychiatric disorder, schizophrenia, mania, depression (within past 24 months) or under any concurrent medical, cognitive or psychiatric condition that would either: compromise his/her ability to comply with the study requirements, may pose significant risk to the subject, or be deemed exclusionary by the Principal Investigator
• History of heavy smoking (> 1 pack/day) within past 3 months
• History of heavy caffeinated beverage consumption (> 400 mg caffeine/day) within past 2 weeks
• Taking any supplements or vitamins notably known to affect cognitive function (e.g. Living Nutrition Cognitive, Viridian Cognitive Complex, fish oil etc., list not exhaustive), or any psychotropic medications and products which interact with acetylcholine esterase and/or NMDA receptors (6-week washout before screening). Vitamin D and Calcium supplements permitted if on a stable dose for the previous 3 months
• Participant with history of drug and/or alcohol abuse at the time of enrolment
• Significant change of dietary habits within the preceding month
• With known organic disease, including an inflammatory bowel disease, a benign or malign tumour of intestine or colon or significant systemic disease, and with history of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years
• Participant with known allergy to components of the test product or with a medical history of food allergies
• Having uncontrolled hypertension, uncontrolled hypothyroidism or hyperthyroidism or uncontrolled lipidaemia (hypercholesteremia or hypertriglyceridemia) that is not on stable medication for at least 3 months.
• Current illnesses which could interfere with the study (e.g. prolonged severe diarrhoea, regurgitation/severe, difficulty swallowing)
• Participants taking any anticoagulant (including aspirin) or heparin treatment
• Participant currently involved in any other clinical trial or having participated in a trial within the preceding 90 days
• Individuals who are unable to give informed consent
• Participant has a history of non-compliance with medical treatments or recommendations
• Occupations that resulted in disruption of sleep-wake cycles
• Participant has difficulty hearing with or without a hearing aid or is colour blind or is visually impaired

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: TPG; 76 participants who meet the eligibility criteria will be randomized under experimental arm and will receive Turmipure GOLD® product during 24 weeks	Dietary supplement: Turmipure Gold®; TPG: Turmipure GOLD® - 1 capsule per day - as prescribed
Placebo Comparator: Control; 76 participants who meet the eligibility criteria will be randomized under experimental arm and will receive placebo (colored acacia gum) product during 24 weeks	Dietary supplement: Placebo; Placebo: colored acacia gum - 1 capsule per day - as prescribed

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in cognitive performance through Quality of Working memory	Quality of Working memory is a composite score determined by the CDR System™ test battery (unit: #)	24 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in cognitive performance through Power of Attention	Power of Attention is a composite score determined by the CDR System™ test battery (unit: ms)	24 weeks
Change in cognitive performance through Continuity of Attention	Continuity of Attention is a composite score determined by the CDR System™ test battery (unit: #)	24 weeks
Change in cognitive performance through Cognitive Reaction Time	Cognitive Reaction Time is a composite score determined by the CDR System™ test battery (unit: ms)	24 weeks
Change in cognitive performance through Speed of Memory	Speed of Memory is a composite score determined by the CDR System™ test battery (unit: ms)	24 weeks
Change in cognitive performance through Quality of Episodic Memory	Quality of Episodic Memory is a composite score determined by the CDR System™ test battery (unit: #)	24 weeks
Change in cognitive performance through Quality of Memory	Quality of Memory is a composite score determined by the CDR System™ test battery (unit: #)	24 weeks
Change in cognitive performance through Executive Function	Executive Function is a composite score determined by the CDR System™ test battery (unit: #)	24 weeks
Change in stress	Stress will be assessed using the validated scale Perceived Stress Scale (0 to 56, higher scores meaning at maximum stress)	24 weeks
Change in feelings and emotions	Mood will be assessed using the validated Positive and Negative Affect Schedule - Expanded Form (PANAS-X) questionnaire	24 weeks
Change in mood	Mood will be assessed using the validated Bond-Lader questionnaire	24 weeks

Collaborators and Investigators

• Sponsor: Naturex SA
• Collaborators: Atlantia Food Clinical Trials
• Investigators: Principal Investigator: Timothy Dinan, Professor, Atlantia Clinical Food Trials

Study record dates

Study Major Dates

• Study Start (Actual): April 19, 2021
• Primary Completion (Actual): August 10, 2023
• Study Completion (Actual): August 10, 2023

Study Registration Dates

• First Submitted: April 13, 2021
• First Submitted That Met QC Criteria: April 22, 2021
• First Posted (Actual): April 26, 2021

Study Record Updates

• Last Update Posted (Estimated): January 18, 2024
• Last Update Submitted That Met QC Criteria: January 17, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: Turmeric; Curcuminoids
• Other Study ID Numbers: AFCRO-125

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No